Analysis of Inventory
Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Current Ratio since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Inventory Disclosure
Pfizer Inc., balance sheet: inventory
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Finished goods | |||||||||||
| Work-in-process | |||||||||||
| Raw materials and supplies | |||||||||||
| Inventories |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The annual financial data reveals specific patterns in inventory components over the five-year period from 2020 to 2024.
- Finished Goods
- The value of finished goods exhibited fluctuations during the period. It increased from 2,878 million USD in 2020 to 3,641 million USD in 2021, then declined to 2,603 million USD in 2022. Subsequently, it rose again to 3,495 million USD in 2023 and further to 3,775 million USD in 2024. Overall, the trend suggests volatility with a general upward movement towards the end of the period.
- Work-in-Process
- Work-in-process inventory showed a consistent upward trajectory. Starting at 4,430 million USD in 2020, it slightly decreased marginally to 4,424 million USD in 2021 but then increased steadily each year, reaching 5,519 million USD in 2022, 5,687 million USD in 2023, and 6,100 million USD in 2024. This indicates growing investment in goods under production.
- Raw Materials and Supplies
- This category experienced moderate variability. The value increased from 738 million USD in 2020 to 994 million USD in 2021, then declined to 859 million USD in 2022. It rose again in 2023 to 1,007 million USD before slightly decreasing to 976 million USD in 2024. Despite some fluctuations, the values remained higher than at the beginning of the period.
- Total Inventories
- The aggregated inventory value showed a clear upward trend. From 8,046 million USD in 2020, it rose to 9,059 million USD in 2021. Although it experienced a minor decline in 2022 to 8,981 million USD, the figure increased substantially thereafter, reaching 10,189 million USD in 2023 and 10,851 million USD in 2024. This overall growth in inventories suggests an increase in stockholding and possibly production scale over the period analyzed.
In summary, while finished goods and raw materials demonstrated some volatility, work-in-process and total inventories reflected a generally increasing pattern. This could indicate strategic inventory buildup or response to market demands and operational scaling within the company during these years.